The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue) biomarkers will better predict early brain tumor response to treatments and will be more reliable prognostic markers in patients with malignant brain tumors.

Inclusion Criteria:

• Newly diagnosed or suspected high grade glioma ≥ 1cm in diameter on postoperative anatomic imaging (contrast MRI), prior to initiation of chemoXRT
• Anticipated survival ≥6 months
• Able to give informed consent
• Capable of undergoing MRI and PET scans without the need for sedation or general anesthesia
• Male or Female

Exclusion Criteria:

• Prior radiation therapy and chemotherapy to the brain
• Active intracranial infection or nonglial brain mass.
• Recent large intracranial hemorrhage (<1 month)
• Expected survival <6 months
• Pregnant or nursing
• Renal failure
• Lives far from BWH and/or is unwilling/ unable to return for scheduled imaging visits.

Patients presenting to BWH/DFCI emergency department (ED), inpatient, or neurology/ neurosurgery/ radiation oncology clinics with newly diagnosed brain masses (suspected high grade gliomas) will be consented and enrolled in this study after adequate explanation of the risks and benefits of the study.